Market closedNon-fractional
Exact Sciences/EXAS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Exact Sciences
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.
Ticker
EXAS
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Madison, United States
Employees
6,550
Website
www.exactsciences.com
Exact Sciences Metrics
BasicAdvanced
$8.9B
Market cap
-
P/E ratio
-$1.33
EPS
1.26
Beta
-
Dividend rate
Price and volume
Market cap
$8.9B
Beta
1.26
Financial strength
Current ratio
2.568
Quick ratio
2.046
Long term debt to equity
79.104
Total debt to equity
79.104
Interest coverage (TTM)
-11.98%
Management effectiveness
Return on assets (TTM)
-3.15%
Return on equity (TTM)
-7.76%
Valuation
Price to revenue (TTM)
3.455
Price to book
2.83
Price to tangible book (TTM)
-8.05
Price to free cash flow (TTM)
-175.796
Growth
Revenue change (TTM)
15.21%
Earnings per share change (TTM)
-54.46%
3-year revenue growth (CAGR)
17.93%
3-year earnings per share growth (CAGR)
-33.94%
What the Analysts think about Exact Sciences
Analyst Ratings
Majority rating from 23 analysts.
Exact Sciences Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$638M
-1.44%
Net income
-$110M
121.73%
Profit margin
-17.28%
125.00%
Exact Sciences Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.45
-
-$0.27
-$0.60
-
Expected
-$0.51
-$0.48
-$0.46
-$0.47
-$0.31
Surprise
-11.68%
-
-41.21%
27.32%
-
Exact Sciences News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Exact Sciences stock?
Exact Sciences (EXAS) has a market cap of $8.9B as of July 27, 2024.
What is the P/E ratio for Exact Sciences stock?
The price to earnings (P/E) ratio for Exact Sciences (EXAS) stock is 0 as of July 27, 2024.
Does Exact Sciences stock pay dividends?
No, Exact Sciences (EXAS) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Exact Sciences dividend payment date?
Exact Sciences (EXAS) stock does not pay dividends to its shareholders.
What is the beta indicator for Exact Sciences?
Exact Sciences (EXAS) has a beta rating of 1.26. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Exact Sciences stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.